featured-image

PERTH, Australia , July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company with NovaCina CDMO division and LumaCina pharmaceutical supply division, announces the addition of renown Australian executive John Van Der Wielen to Board of Directors. Van Der Wielen will focus on Australian expansion programs for all three entities. Van Der Wielen brings a wealth of global experience and strategic insight to the Board, globally and within Australia .

His extensive accomplishments in corporate strategy across diverse industries, including the health industry, plus his proven track record of driving growth and innovation, makes him a valuable asset to the company's leadership team. "John's appointment to our board marks a significant milestone for Bridgewest Perth Pharma," said Dr. Masood Tayebi , Co-Founder and CEO of Bridgewest Group.



"His expertise will be instrumental as we continue to expand our operations and explore new opportunities within the pharmaceutical sector. We are thrilled to welcome John to our team and look forward to his contributions in guiding our strategic direction." Van Der Wielen is currently the Chair for Orthocell Ltd.

and Crown Resorts Perth. Previously, he was Chair of the Future Health Innovation and Research Fund WA, Director at Royal Flying Doctor Service (WA), and CEO of one of Australia's largest health insurance funds. "I am very excited to be involved with Bridgewest Group and Bridgewest Perth Pharma," said Van D.

Back to Health Page